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Abstract 
Background: The consumption of nuts has been associated with a reduction of cancer risk, but 
only a few studies have examined the effects of nuts on prostate cancer risk. The current study 
prospectively investigated the association between the consumption of total nuts, tree nuts, 
peanuts, and peanut butter and the risk of total, advanced, and non-advanced prostate cancer. 
Methods: The association between nuts and prostate cancer was evaluated in the Netherlands 
Cohort Study, which was conducted among 58 279 men aged 55-69 year at baseline. A case-
cohort approach was used for data processing and analyses. After 20.3 years of follow-up, 
3868 incident prostate cancer cases and 1979 subcohort members were available for 
multivariable Cox regression analyses. 
Results: For total, advanced, and non-advanced prostate cancer, no significant associations 
were found for total nuts (total prostate cancer: hazard ratio (HR) (95%CI) for 10+ g/day vs. 
non-consumers = 1.09 (0.92-1.29), Ptrend = 0.409). No significant associations were observed 
for tree nuts and peanuts for total, advanced, and non-advanced prostate cancer risk. Peanut 
butter consumption was associated with a significantly increased risk of non-advanced 
prostate cancer (HR (95%CI) for 5+ g/day vs. non-consumers = 1.33 (1.08-1.63), Ptrend = 
0.008), but not with total or advanced prostate cancer. 
Conclusions: No significant associations were found between total nut, tree nut, and peanut 
consumption and total, advanced, and non-advanced prostate cancer. Peanut butter might be 
associated with an increased non-advanced prostate cancer risk. 
 
Introduction 
Prostate cancer is the second most common cancer and the fifth leading cause of cancer death 
in men worldwide1. Several studies have investigated the association between etiological 
factors and prostate cancer risk, but the evidence has not been consistent2. This might be due 
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to the heterogeneous nature of prostate cancer. Studies have indicated that risk factors for 
advanced and non-advanced prostate cancer differ, which can most likely be explained by the 
way they act on biological pathways3. Advanced prostate cancer cases have a higher 
diagnostic certainty, and often have stronger associations with etiological factors than non-
advanced prostate cancer cases. Non-advanced prostate cancer cases can therefore dilute the 
association towards the null if only total prostate cancer cases are investigated2,3. Three risk 
factors for prostate cancer have been well-established: age, ethnicity, and a positive family 
history of prostate cancer3,4. Potential risk factors for prostate cancer for which moderate to 
strong evidence from meta-analyses is available include body mass index (BMI) and height, 
and potential risk factors for which limited evidence is available include diabetes mellitus 
type 2, alcohol consumption, smoking, physical activity, and diet5-14, whereby the associations 
are often more pronounced for advanced than for non-advanced prostate cancer.  
 
One food group that has a potential to reduce prostate cancer risk are nuts. Nut intake has 
consistently been associated with a reduction of several chronic conditions, including cancer 
risk and cancer-related mortality15-17. Although the exact mechanism is unclear, it is suggested 
that their beneficial impact relates to their antioxidant and anti-inflammatory properties18,19. 
 
Only two prospective studies20,21 and three case-control studies22-24 have examined the 
association between the consumption of nuts and prostate cancer incidence or mortality. They 
show inconsistent results, demonstrating either a protective or a non-significant association. 
Moreover, studies that investigated the different effects on advanced and non-advanced 
prostate cancer risk are limited. The aim of the current study is to prospectively investigate 
the association between the consumption of total nuts, tree nuts, peanuts, and peanut butter, 
and the risk of total, advanced, and non-advanced prostate cancer. 
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Methods 
Study design and population 
The current study was performed within the Netherlands Cohort Study (NLCS). The study 
started on 17 September 1986 and included 58 279 men. A detailed description of the study is 
reported elsewhere25. For efficiency reasons, a case-cohort design was used, with cases 
derived from the entire cohort and the person-years at risk estimated in a subcohort. At 
baseline, participants consented to participate by completing and returning a mailed self-
administered questionnaire, including a 150-item semi-quantitative food frequency 
questionnaire (FFQ). A subcohort of 2411 men was randomly selected from the full cohort at 
the time of baseline measurement. Data on vital status was collected in the subcohort during 
the follow-up period of 20.3 years follow-up (until 31 December 2006), and was 100% 
complete. Ethical clearance was obtained from the University Hospital Maastricht 
(Maastricht, the Netherlands) and the Netherlands Organisation for applied scientific research 
(TNO). 
 
Data on incident prostate cancer cases in the entire cohort were collected using record linkage 
with the Netherlands Cancer Registry and the Dutch National Pathology Registry (PALGA)26. 
All cases were microscopically verified. The completeness of the cancer incidence follow-up 
was estimated to be at least 96%27. Prostate cancer cases were classified using the guidelines 
of the International Union Against Cancer, with non-advanced prostate cancer cases classified 
as stage T1 or T2 and N0 and M0, and advanced prostate cancer cases classified as stage T3 
or T4, N+, or M1.  
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A flow diagram of the number of subcohort members and cases in the current study can be 
found in Figure 1. Cases and subcohort members with prevalent cancer (except for skin 
cancer) at baseline, with incomplete or inconsistent dietary data, or missing data on 
confounding variables were excluded from the analysis28. The study population in the current 
study includes 1979 subcohort members and 3868 incident prostate cancer cases diagnosed 
during the 20.3 years follow-up. Of these cases, 2329 were classified as non-advanced 
prostate cancer cases and 1256 as advanced prostate cancer cases. The classification for 283 
cases was unclear. 
 
Exposure measurement 
The baseline questionnaire measured potential risk factors for cancers, including 
anthropometry, smoking habits, physical activity, and disease history. A validated FFQ 
assessed habitual diet in the preceding year28. The frequency of consumption of ‘peanuts’, 
‘other nuts, mixed nuts’ (tree nuts), and ‘peanut butter’ was measured based on the following 
range: ‘never or less than 1 time/month’ to ‘6-7 times per week’. In addition, the number of 
standard portion sizes per intake was reported by participants. The standard portion size was 
28 grams for tree nuts and peanuts, and 15 grams per slice of bread for peanut butter. The 
mean daily intake of nuts was calculated in grams, by multiplying the frequency of 
consumption by portion sizes. Total nut consumption consisted of peanut and tree nut intake. 
The personnel that were involved in entry, coding, and interpretation of the questionnaire 
were blinded to the case/subcohort status of the participations. 
 
Statistical analysis 
Cox proportional hazard models were used to estimate hazard ratios (HRs) and 95% CIs. The 
consumption of total nuts, tree nuts, peanuts, and peanut butter were analysed separately, both 
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on a categorical and continuous scale. Categories were divided as follows: 0, 0.1-<5, 5-<10, 
and 10+ g/day for total nuts and peanuts, and 0, 0.1-<5, and 5+ g/day for tree nuts and peanut 
butter. The intake category of 0 g/day was used as reference group. The median value of nut 
consumption per category in the subcohort was used as a continuous variable in a Cox 
regression model to assess linear trends. For the continuous analyses, results were expressed 
in HRs per 5 g/day increment. All analyses were performed for total, non-advanced, and 
advanced prostate cancer, and Wald tests were performed to evaluate the statistical 
significance.  
 
To control for the additional variance introduced by using the person-years at risk from the 
subcohort, a Huber-White sandwich estimator was used to calculate standard errors29. The 
proportional hazards assumption was tested with the scaled Schoenfeld residuals, -log-log 
survival plots, and time-covariate interaction terms. No violation of this assumption was 
observed for the exposure variables. Time-varying covariates were included in the model if 
the assumption was violated for confounders. 
 
Factors that are known or hypothesized to be associated with prostate cancer and nut intake 
based on literature were assessed as confounders. Predefined confounders were included in 
the final model irrespective of their effect on the estimates, and include: age (years; 
continuous), family history of prostate cancer (yes/no), alcohol consumption (g/day; 
continuous), level of education (primary school or lower vocational education 
(low)/secondary school or medium vocational education (medium)/university or higher 
vocational education (high)), BMI (<18.5/18.5-<25/25-<30/≥30 kg/m2), and total energy 
intake (kcal/day; continuous). Potential confounders include: height (cm; continuous), non-
occupational physical activity (≤30/>30-≤60/>60-≤90/>90 min/day), cigarette smoking status 
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(never/former/current), cigarette smoking frequency (n/day; continuous centred), cigarette 
smoking duration (years; continuous centred), history of diabetes (yes/no), nutritional 
supplement use (yes/no), tea consumption (<1 times per week/1-<2 times per week/2-<4 
times per week/4-<5 times per week/≥5 times per week), intake of fruit (g/day; continuous), 
and intake of vegetables (g/day; continuous). Potential confounders were included if the 
variable changed the HR by at least 10% when using a backward stepwise selection 
procedure. In the final multivariable-adjusted model, only the predefined confounders were 
included.  
 
For the interaction analysis, the following predefined strata were considered: family history of 
prostate cancer (yes/no), baseline BMI (18.5-<25/≥25 kg/m2), alcohol consumption (0/0.1-
<15/≥15 g/day), and educational level (low/medium/high). To test for interactions, cross-
product terms were included in the Cox regression models, and Wald tests were performed. 
Participants with a BMI <18.5 kg/m2 were deleted from the interaction analysis to increase 
statistical power. 
 
The analysis was repeated with the first 2 years of follow-up excluded to assess whether 
preclinical disease influenced the observed associations. Besides, all nut and peanut butter 
consumers were excluded from the reference group to assess whether this would substantially 
change the results. Lastly, the analyses were repeated with mutual adjustment for the effects 
of other nut groups. 
 
Statistical analysis were performed using Stata software (Version 15.0; Stata Corporation, 
College Station, TX), and differences were considered statistically significant at P<0.05 for 
two-sided testing.  
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Results 
The mean consumption (SD) of total nuts, tree nuts, peanuts, and peanut butter in the male 
subcohort was 7.8 (13.8), 1.0 (3.3), 6.8 (13.1), and 1.4 (4.1) g/day, respectively. Baseline 
characteristics are presented in Table 1. As compared to the subcohort, total prostate cancer 
cases more often had a family history of prostate cancer, less often had a history of diabetes, 
and they were higher educated. 
 
Table 2 presents the age- and multivariable-adjusted HRs for total, advanced, and non-
advanced prostate cancer according to total nut, tree nut, peanut, and peanut butter 
consumption. In the age-adjusted model, no significant associations were observed for the 
highest versus the lowest intake category of total nuts, tree nuts, and peanuts in total, 
advanced, and non-advanced prostate cancer cases. Peanut butter intake was associated with a 
statistically significant increased risk of non-advanced prostate cancer, but not with total or 
advanced prostate cancer. The addition of covariates to the multivariable-adjusted model 
slightly attenuated the HRs as compared to the age-adjusted model. In the multivariable-
adjusted analysis of total prostate cancer, no significant association was found for total nuts 
(HR (95%CI) for 10+ g/day vs. non-consumers = 1.09 (0.92-1.29), Ptrend = 0.409). Also no 
significant associations were found for tree nuts, peanuts, or peanut butter in total prostate 
cancer cases. In advanced prostate cancer cases, no significant association was found for total 
nuts (HR (95%CI) for 10+ g/day vs. non-consumers = 1.07 (0.87-1.33), Ptrend = 0.650), and 
also not for tree nut, peanut, or peanut butter consumption. In non-advanced prostate cancer 
cases, no significant association was found for total nuts (HR (95%CI) for 10+ g/day vs. non-
consumers = 1.12 (0.93-1.35), Ptrend = 0.341), or for tree nuts or peanuts. However, peanut 
butter consumption was significantly associated with an increased risk of non-advanced 
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prostate cancer in the multivariable-adjusted analysis (HR (95%CI) for 5+ g/day vs. non-
consumers = 1.33 (1.08-1.63), Ptrend = 0.008), and in the continuous analysis (HR per 5 g/day 
increment (95%CI) = 1.09 (1.01-1.17)).  
 
The associations between total nut consumption and total prostate cancer risk in strata of 
potential effect modifiers are presented in Table 3. The intake categories 5-<10 g/day and 10+ 
g/day were merged to increase statistical power. No significant interactions were observed for 
family history of prostate cancer, BMI, alcohol consumption, and level of education in the 
analyses for total (Table 3), advanced, and non-advanced prostate cancer (data not shown). 
Besides, no interactions were observed for peanut butter in non-advanced prostate cancer 
cases (data not shown). In a sensitivity analysis, exclusion of the first two years of follow-up, 
exclusion of all nut and peanut butter consumers from the reference group, or mutual 
adjustment for the effects of other nut groups, did not importantly change the results (data not 
shown). 
 
Discussion 
We observed no significant associations between total nut, tree nut, and peanut consumption 
and total, advanced, and non-advanced prostate cancer risk. No association was observed for 
peanut butter in total and advanced prostate cancer cases, but higher intake of peanut butter 
was associated with a significantly increased risk of non-advanced prostate cancer. No 
significant interactions with potential effect modifiers were observed with total nut 
consumption in total, advanced, and non-advanced prostate cancer cases. 
  
To our knowledge, two cohort studies20,21 and three case-control studies22-24 have examined 
the association between nut consumption and prostate cancer risk. The large prospective 
10 
 
Health Professionals Follow-Up Study and the Adventists Health Study both reported no 
significant associations between total nut consumption and total prostate cancer risk20,21. 
Thus, cohort studies consistently show no association between nut intake and prostate cancer 
risk, which is in line with our study. One case-control study also demonstrated no significant 
association between total nut consumption and total prostate cancer risk22. In contrast, two 
case-control studies demonstrated significantly decreased risks for total prostate cancer23,24. A 
random-effects meta-analysis (including one cohort study and four case-control studies; of 
which three studies have been mentioned above) demonstrated a decreased risk of total 
prostate cancer, albeit not statistically significant16. Two case-control studies that were 
included in the meta-analysis, but are not mentioned above, used different reference 
categories as they compared different diets, and combined the intake of nuts with different 
food groups. There are several limitations to this meta-analysis, including a high 
heterogeneity (I2=59.7%) and the inclusion of case-control studies that are possibly prone to 
recall bias and selection bias. To our knowledge, no study has examined the differential 
effects of tree nuts, peanuts, and peanut butter. 
 
Only two studies have examined the differential effects of total nut consumption on total 
prostate cancer and advanced prostate cancer. One case-control study demonstrated no 
significant association for aggressive prostate cancer22. The prospective Health Professionals 
Follow-up Study found no significant association for advanced prostate cancer and total nut 
consumption20, which is consistent with our findings. 
 
The increased risk of non-advanced prostate cancer for increased intake of peanut butter in 
our study is unexpected, as it is in contrast with the hypothesis that advanced prostate cancer 
cases have stronger associations with etiological factors. Furthermore, it is remarkable that an 
11 
 
association was found for peanut butter consumption and not for peanut consumption. 
Additional analysis of lifestyle differences between consumers and non-consumers of peanut 
butter in the subcohort did not indicate the potential for residual confounding (data not 
shown). Although we acknowledge that our estimates might be a result of chance findings, we 
tried to elucidate the mechanisms underlying the association. In 1986, in the year of exposure 
measurement, peanut butter contained more partially hydrogenated fatty acids (trans-fats) as 
compared to peanuts15,30. Several studies have indicated that trans-fatty acid markers are 
associated with an increased prostate cancer risk31. The intake of trans-fats increases 
systematic inflammation and insulin resistance, which both have been associated with prostate 
carcinogenesis31. The Physician’s Health Study demonstrated that high blood concentrations 
of trans-fatty acids were unrelated to total or aggressive prostate cancer risk, but were 
associated with an increased risk of non-aggressive prostate tumors31. The SELECT study 
demonstrated that high blood levels of trans-fatty acids were associated with a reduced, albeit 
non-significant risk of high-grade prostate cancer, while a non-significant increased risk of 
low-grade prostate cancer was demonstrated32. The specific mechanisms explaining why 
peanut butter increases the risk of non-advanced prostate cancer remain unclear. As our 
observations alternatively might be a result of chance findings, no firm conclusions can yet be 
drawn. 
 
Strengths of the current study are the prospective design and the long follow-up with excellent 
retention. The potential for selection bias and information bias is therefore limited. Cases with 
inconsistent or incomplete dietary data, or cases with missing data on confounding variables 
were excluded from analysis, which might have introduced selection bias if the data was not 
missing completely at random. Furthermore, information bias might have been introduced 
because of self-reported baseline measurement. As exposure and confounders were only 
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measured at baseline, exposure trends over time could not be detected, which might have 
introduced measurement error. We have no data on tree nut subtypes, and thus tree nuts were 
analysed as one group. Because not all tree nuts are comparable in nutritional composition33, 
future studies should investigate the effect of specific types of tree nuts on the risk of prostate 
cancer. 
 
In conclusion, we have demonstrated that the consumption of total nuts, tree nuts, and peanuts 
is not significantly associated with total, advanced, and non-advanced prostate cancer risk. 
However, peanut butter intake might be associated with an increased non-advanced prostate 
cancer risk. Further research is imperative to resolve the relation of peanut butter and non-
advanced prostate cancer, and to determine the risk-benefit trade-offs associated with dietary 
intake of peanut butter.  
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Figure legends 
Figure 1. Flow diagram of included cases and subcohort member 

Table 1. Baseline characteristics (mean (SD) or percentage) of subcohort members and prostate cancer cases from the Netherlands Cohort Study,  
1986-2006 
 Subcohort 
 
Prostate cancer 
 Total Advanced Non-advanced 
N* 1979 3868 1256 2329 
Age (years) 61.3 (4.2) 61.8 (4.1) 61.7 (4.1) 61.6 (4.1) 
Height (cm) 176.5 (6.6) 176.6 (6.7) 176.5 (6.4) 176.8 (6.8) 
BMI (kg/m2) 24.9 (2.6) 25.0 (2.5) 25.0 (2.5) 24.9 (2.5) 
Non-occupational physical activity 
(min/day) 
80.8 (67.7) 79.9 (61.9) 77.9 (59.9) 80.7 (62.9) 
Ever smokers (%) 87.2 85.5 85.9 85.1 
Higher vocational school or university (%) 19.7 23.0 20.8 24.6
Family history of prostate cancer (%) 2.4 3.5 3.3 3.7 
History of diabetes (%) 3.2 2.7 2.8 2.7 
Dietary intake  
Intake of total nuts (g/day) 7.8 (13.8) 8.3 (15.2) 8.5 (16.5) 8.3 (14.6) 
Intake of tree nuts (g/day) 1.0 (3.3) 1.1 (3.8) 1.1 (3.9) 1.1 (3.7) 
Intake of peanuts (g/day) 6.8 (13.1) 7.1 (14.1) 7.4 (15.6) 7.1 (13.3)
Intake of peanut butter (g/day) 1.4 (4.1) 1.6 (4.4) 1.5 (4.2) 1.8 (4.7) 
Total energy intake (kcal/day) 2166 (498) 2159 (487) 2169 (493) 2164 (482) 
Alcohol consumption (g/day) 15.1 (17.0) 14.9 (15.6) 14.8 (15.3) 14.9 (15.6) 
Tea consumption ≥2 cups/day (%) 68.5 69.4 67.2 70.2
Intake of fruit (g/day) 154.8 (114.4) 161.5 (111.8) 157.1 (109.7) 164.8 (112.6) 
Intake of vegetables (g/day) 186.5 (75.6) 188.8 (73.4) 190.1 (75.7) 188.7 (72.3) 
Nutritional supplement user (%) 23.2 23.9 22.8 24.3
*excluding participants with prevalent cancer (except for skin cancer) at baseline, incomplete or inconsistent dietary data, or missing data on confounding 
variables (age, family history of prostate cancer, level of education, energy intake, alcohol consumption, and body mass index) 
Table 2. Age- and multivariable-adjusted HRs (95%CI) for total, advanced, and non-advanced prostate cancer according to nut consumption, the 
Netherlands Cohort Study, 1986-2006 
 
Food item 
(g/day) 
 
Median 
intakea 
 
Person
-yearsb 
 
Total prostate cancer  Advanced prostate cancer  Non-advanced prostate cancer 
Cases Age-adjusted 
HR (95%CI) 
Multivariable- 
adjusted HR 
(95%CI)c 
 Cases Age-adjusted 
HR (95%CI) 
Multivariable-
adjusted HR 
(95%CI)c 
 Cases Age-adjusted 
HR (95%CI) 
Multivariable- 
adjusted HR 
(95%CI)c 
Total nuts               
0 0.0 9393 1141 1.00 (ref) 1.00 (ref)  377 1.00 (ref) 1.00 (ref)  662 1.00 (ref) 1.00 (ref) 
0.1-<5 2.5 10 023 1291 1.08 (0.93–1.25) 1.05 (0.91–1.22)  424 1.08 (0.89–1.30) 1.05 (0.87–1.27)  777 1.11 (0.95–1.31) 1.08 (0.91–1.27) 
5-<10 8.5 4148 503 1.03 (0.85–1.25) 0.99 (0.81–1.20)  150 0.93 (0.73–1.20) 0.89 (0.69–1.15)  323 1.12 (0.91–1.38) 1.07 (0.86–1.33) 
10+ 21.4 7252 933 1.13 (0.96–1.32) 1.09 (0.92–1.29)  305 1.11 (0.91–1.36) 1.07 (0.87–1.33)  567 1.16 (0.97–1.38) 1.12 (0.93–1.35) 
P-trend    0.244 0.409   0.435 0.650   0.185 0.341 
Continuous 
per 5 g/day 
   1.01 (0.99–1.03) 1.01 (0.98–1.03)   1.01 (0.99–1.04) 1.01 (0.98–1.04)   1.01 (0.98–1.03) 1.00 (0.98–1.03) 
Tree nuts              
0 0.0 22 309 2773 1.00 (ref) 1.00 (ref)  912 1.00 (ref) 1.00 (ref)  1655 1.00 (ref) 1.00 (ref) 
0.1-<5 1.6 6963 886 1.04 (0.90–1.20) 1.00 (0.87–1.16)  284 1.02 (0.85–1.21) 1.00 (0.84–1.20)  539 1.05 (0.90–1.23) 1.00 (0.85–1.17) 
5+ 8.6 1544 209 1.11 (0.85–1.45) 1.10 (0.84–1.44)  60 0.97 (0.69–1.37) 0.97 (0.68–1.37)  135 1.19 (0.89–1.58) 1.17 (0.88–1.57) 
P-trend    0.402 0.503   0.910 0.860   0.211 0.308 
Continuous 
per 5 g/day 
   1.03 (0.95–1.13) 1.01 (0.93–1.11)   1.02 (0.92–1.14) 1.01 (0.90–1.13)   1.04 (0.95–1.14) 1.01 (0.92–1.11) 
Peanuts              
0 0 10 550 1281 1.00 (ref) 1.00 (ref)  414 1.00 (ref) 1.00 (ref)  751 1.00 (ref) 1.00 (ref) 
0.1-<5 2.5 10 952 1407 1.10 (0.96–1.26) 1.07 (0.93–1.23)  460 1.11 (0.93–1.33) 1.08 (0.90–1.30)  855 1.12 (0.96–1.31) 1.09 (0.93–1.28) 
5-<10 8.5 3362 415 1.10 (0.89–1.35) 1.06 (0.86–1.31)  131 1.07 (0.83–1.39) 1.03 (0.79–1.35)  260 1.15 (0.92–1.44) 1.11 (0.89–1.40) 
10+ 21.4 5952 765 1.14 (0.96–1.35) 1.11 (0.93–1.33)  251 1.16 (0.94–1.43) 1.12 (0.89–1.40)  463 1.15 (0.96–1.39) 1.12 (0.93–1.37) 
P-trend    0.219 0.332   0.291 0.454   0.226 0.352 
Continuous 
per 5 g/day 
   1.01 (0.99–1.03) 1.01 (0.98–1.03)   1.01 (0.99–1.04) 1.01 (0.98–1.04)   1.00 (0.98–1.03) 1.00 (0.98–1.03) 
Peanut 
butter 
             
0 0.0 22 148 2695 1.00 (ref) 1.00 (ref)  885 1.00 (ref) 1.00 (ref)  1593 1.00 (ref) 1.00 (ref) 
0.1-<5 1.2 5290 701 1.15 (0.99–1.35) 1.14 (0.97–1.33)  229 1.14 (0.94–1.39) 1.14 (0.94–1.39)  424 1.18 (0.99–1.39) 1.15 (0.97–1.37) 
5+ 9.6 3379 472 1.19 (0.99–1.44) 1.19 (0.99–1.44)  142 1.09 (0.86–1.38) 1.08 (0.85–1.38)  312 1.33 (1.08–1.62) 1.33 (1.08–1.63) 
P-trend    0.071 0.072   0.485 0.526   0.007 0.008 
Continuous 
per 5 g/day 
   1.05 (0.98–1.12) 1.06 (0.99–1.13)   1.02 (0.94–1.10) 1.02 (0.94–1.11)   1.08 (1.00–1.15) 1.09 (1.01–1.17) 
a Median intake in the subcohort b Person-years in the subcohort c Adjusted for: age (years; continuous), family history of prostate cancer (yes/no), body mass 
index (<18.5/18.5-<25/25-<30/30+ kg/m2), alcohol consumption (0/0.1-<5/5-<15/15-<30/≥30 g/day), level of education (primary or lower vocational/secondary 
or medium vocational/university or higher vocational), and total energy intake (kcal/day; continuous) 
Table 3. Multivariable-adjusteda HRs (95%CI) for total prostate cancer according to total nut consumption in subgroups, the Netherlands Cohort 
Study, 1986-2006 
 Total nut consumption (g/day) (medianb) Ptrend Pinteraction 
 0 g/day 0.1-<5 g/day 5+ g/day   
Overall      
 Cases/person-time at risk 1141/9393 1291/10023 1436/11400 0.688  
 HR (95%CI) 1.00 (reference) 1.05 (0.90–1.22) 1.05 (0.90-1.22)   
Family history of prostate cancer     0.114 
Yes Cases/person-time at risk 40/167 43/171 54/430 0.071  
 HR (95%CI) 1.00 (reference) 1.50 (0.52–4.36)  0.56 (0.20–1.53)    
No Cases/person-time at risk 1101/9226 1248/9852 1382/10970 0.400  
 HR (95%CI) 1.00 (reference) 1.05 (0.90–1.22) 1.08 (0.93–1.26)   
Body mass index     0.149 
18.5-<25 kg/m2 Cases/person-time at risk 618/4726 681/5600 755/6116 0.982  
 HR (95%CI) 1.00 (reference) 0.91 (0.74–1.12) 0.96 (0.78–1.18)   
≥25 kg/m2 Cases/person-time at risk 520/4634 608/4398 676/5271 0.534  
 HR (95%CI) 1.00 (reference) 1.24 (1.00–1.54) 1.15 (0.92–1.44)   
Alcohol consumption     0.805 
0 g/day Cases/person-time at risk 239/2236 142/1203 107/798 0.262  
 HR (95%CI) 1.00 (reference) 1.14 (0.79–1.65) 1.29 (0.84–1.99)   
0.1-<15 g/day Cases/person-time at risk 505/4047 740/5544 646/5221 0.973  
 HR (95%CI) 1.00 (reference) 1.10 (0.88–1.36) 1.04 (0.83–1.29)   
≥15 g/day Cases/person-time at risk 397/3109 409/3277 683/5380 0.833  
 HR (95%CI) 1.00 (reference) 0.96 (0.74–1.24) 1.01 (0.79–1.27)   
Level of education     0.055 
Low Cases/person-time at risk 538/4913 527/4482 507/3899 0.144  
 HR (95%CI) 1.00 (reference) 1.06 (0.85–1.31) 1.19 (0.94–1.49)   
Medium Cases/person-time at risk 428/3017 476/3570 501/4599 0.045  
 HR (95%CI) 1.00 (reference) 0.98 (0.76–1.27) 0.80 (0.62–1.03)   
High Cases/person-time at risk 175/1463 288/1970 428/2902 0.068  
 HR (95%CI) 1.00 (reference) 1.16 (0.80–1.67) 1.40 (0.98–1.99)   
a Adjusted for: age (years; continuous), family history of prostate cancer (yes/no), body mass index (18.5-<25/25-<30/30+ kg/m2), alcohol consumption (0/0.1-
<5/5-<15/15-<30/≥30 g/day), level of education (primary or lower vocational/secondary or medium vocational/university or higher vocational), and total 
energy intake (kcal/day; continuous) b Median intake in the subcohort 
